CSL Secures Co-Development Rights for Alentis Fibrosis Drug in $1.55B Deal
CSL has agreed to pay $355 million upfront and up to $1.2 billion in milestones to co-develop and co-commercialize Alentis Therapeutics' phase 2 fibrosis drug, lixudebart. The deal grants CSL 55% of profits and funding for trials in kidney and liver diseases, including a phase 3 study for antineutrophil cytoplasmic antibodies-associated vasculitis.